Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Cencora, Inc.

Cencora Inc (COR) has experienced a price drop of 4.3% since Tuesday. Recent social media discussions have highlighted significant activity related...

Cencora Inc reacts to social media buzz on financial dealings. Nittetsu Mining's $1.5M payment for Los Chapitos Copper Project raises concerns.

Cencora Inc. has reported notable insider transactions today. CEO Robert P. Mauch acquired 24,267 shares, increasing his direct holdings to 67,079...

Cencora insiders increased holdings significantly today. Positive market response follows Camino's C$5.6 million investment announcement.

Cencora Inc's CEO, Robert P. Mauch, recently acquired 4,872 shares, increasing his total holdings to 42,812 shares, as reported in a Form 4 filed w...

Cencora's CEO and VP increased their shareholdings, signaling confidence. Analysts affirm a "Buy" rating post-strategic review for growth alignment.

Cencora Inc. has seen a price movement of -0.1% since Tuesday. During market hours, Camino announced a C$5.6 million investment involving strategic...

Cencora Inc. reacts to Camino's C$5.6M strategic investment. Market sentiment shifts as investors assess potential impacts on future growth.

Cencora Inc has received significant upgrades from major analysts today. Wells Fargo has raised its price target to 405 from 354 while maintaining...

Cencora Inc's price targets raised by Wells Fargo and JPMorgan signal strong growth potential. Analysts maintain Overweight ratings, reflecting pos...

Deutsche Bank analyst George Hill has raised the price target on Cencora Inc to 371.00 from 322.00, while maintaining a Buy rating. This adjustment...

Deutsche Bank's George Hill raises Cencora target to 371.00, citing an improved outlook. Maintains Buy rating amid positive market sentiment.

Cencora Inc has experienced upward revisions to its price targets from several analysts today. Mizuho increased its target to 380 from 340, while B...

Analysts raised Cencora's price targets, signaling strong confidence. Positive sentiment stems from rebranding and a $1 billion U.S. supply chain i...

Cencora will invest over $1 billion through 2030 to expand its U.S. network, the drug distributor said on Wednesday, after forecasting adjusted pro...

Cencora to invest $1 billion on US drug distribution, posts upbeat 2026 forecast

The company will open two new distribution centers and expand a third as demand surges for GLP-1s and other refrigerated medications.

Drug Distributor Cencora to Invest $1 Billion in U.S. Supply Chain

Cencora Inc reported its Q4 adjusted earnings per share at 3.84, exceeding the consensus estimate of 3.79 by 1.43%. This reflects a notable increas...

Cencora's Q4 EPS of 3.84 beats estimates, showing growth. The company plans a $1B investment in U.S. supply chain for future expansion.

Cencora Inc is set to announce its Q4 FY2025 earnings before market open on November 5, 2025. The company has provided an EPS estimate of 3.79, up...

Cencora Inc's Q4 FY2025 earnings announcement is imminent. EPS and revenue estimates have significantly improved, reflecting strong growth expectat...

Cencora Inc is set to announce its Q4 FY2025 earnings before market open on November 5, 2025. The company is expected to report an earnings per sha...

Cencora Inc expects strong Q4 FY2025 earnings with EPS rising to 3.79 and revenue to 83.3 billion, boosting investor confidence ahead of the announ...

Cencora Inc's Q4 FY2025 earnings report is due November 5. Analysts predict EPS to rise to 3.79 and revenue to 83.3 billion.

Cencora Inc (NYSE: COR) has seen its stock price increase following a price target adjustment by Mizuho analyst Steven Valiquette, who raised the t...